Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Investing in Malaysia's largest clinic operator to expand the healthcare business
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
The project funding will be done through a mix of internal accruals and debts.
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Subscribe To Our Newsletter & Stay Updated
